Salarius Pharmaceuticals, Inc. Common Stock (SLRX)
Salarius Pharmaceuticals, Inc. (SLRX) is a biotechnology company focused on developing targeted therapies for cancer treatment. The company leverages its proprietary precision oncology platform to identify and develop novel drug candidates aimed at addressing unmet medical needs in various cancer types. Salarius aims to advance therapies that improve patient outcomes through innovative approaches in cancer research.
Company News
Salarius Pharmaceuticals has regained compliance with Nasdaq's Minimum Bid Price Requirement and announced a planned merger with Decoy Therapeutics, a preclinical biopharmaceutical company focused on peptide conjugate therapeutics.
Salarius Pharmaceuticals announced two animal studies supporting the potential of its drug seclidemstat in inhibiting LSD1, a target in cancer treatment. The company is progressing a clinical study at MD Anderson Cancer Center and planning a merger with Decoy Therapeutics.
Salarius Pharmaceuticals is discontinuing its Phase 1/2 clinical trial for the drug seclidemstat in the treatment of Ewing sarcoma. The company is seeking strategic alternatives to maximize shareholder value as it faces financial and operational challenges.
Salarius (SLRX) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Making a list of penny stocks to watch on Robinhood? Here's 4 under $2 to take a look at The post 4 Robinhood Penny Stocks to Watch Under $2 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.